Login to Your Account



Potential $637M to reMYND

Roche, reMYND in Pact to Develop PD, AD Drugs

By Catherine Shaffer


Wednesday, September 15, 2010
Roche AG and reMYND will join forces to develop two classes of compounds against Parkinson's disease and Alzheimer's disease. The total deal is worth as much as $637 million to reMYND as milestones are met. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription